Shenao Zhou, Qianqian Zhang, Jiawei Xu, Ruiqi Xiang, Xiaoping Dong, Xi Zhou, Zhonghua Liu
{"title":"CAP superfamily proteins in human: a new target for cancer therapy.","authors":"Shenao Zhou, Qianqian Zhang, Jiawei Xu, Ruiqi Xiang, Xiaoping Dong, Xi Zhou, Zhonghua Liu","doi":"10.1007/s12032-024-02548-6","DOIUrl":null,"url":null,"abstract":"<p><p>The CAP (Cysteine-rich secretory protein, Antigen 5, and Pathogenesis-related protein 1) superfamily proteins (CAP proteins) are found in all kingdoms of life. The cysteine-rich secreted proteins are prevalent in human organs and tissues and serve as critical signaling molecules within cells, regulating a wide range of biochemical processes in the human body. Due to their involvement in numerous biological processes, CAP proteins have recently attracted significant attention, particularly in the context of tumorigenesis and cancer therapy. This review summarizes the expression patterns and roles of CAP proteins in various cancers. Additionally, it analyzes the mechanisms by which CAP proteins affect cancer cell proliferation and survival, regulate epithelial-mesenchymal transition, influence drug resistance, and regulate epigenetics. The review reveals that CAP proteins play distinct roles in various signaling pathways, such as the MAPK, PI3K-Akt, and p53 pathways, which are crucial for tumor progression. Furthermore, this review summarizes the tumor-inhibiting function of CAP proteins and their potential as cancer biomarkers. These findings suggest that CAP proteins represent a promising new target for innovative cancer diagnosis and treatment.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"41 12","pages":"306"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02548-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The CAP (Cysteine-rich secretory protein, Antigen 5, and Pathogenesis-related protein 1) superfamily proteins (CAP proteins) are found in all kingdoms of life. The cysteine-rich secreted proteins are prevalent in human organs and tissues and serve as critical signaling molecules within cells, regulating a wide range of biochemical processes in the human body. Due to their involvement in numerous biological processes, CAP proteins have recently attracted significant attention, particularly in the context of tumorigenesis and cancer therapy. This review summarizes the expression patterns and roles of CAP proteins in various cancers. Additionally, it analyzes the mechanisms by which CAP proteins affect cancer cell proliferation and survival, regulate epithelial-mesenchymal transition, influence drug resistance, and regulate epigenetics. The review reveals that CAP proteins play distinct roles in various signaling pathways, such as the MAPK, PI3K-Akt, and p53 pathways, which are crucial for tumor progression. Furthermore, this review summarizes the tumor-inhibiting function of CAP proteins and their potential as cancer biomarkers. These findings suggest that CAP proteins represent a promising new target for innovative cancer diagnosis and treatment.
CAP(富含半胱氨酸的分泌蛋白、抗原 5 和致病相关蛋白 1)超家族蛋白(CAP 蛋白)存在于生命的各个领域。富含半胱氨酸的分泌蛋白普遍存在于人体器官和组织中,是细胞内的重要信号分子,调节着人体的各种生化过程。由于参与多种生物过程,CAP 蛋白最近引起了广泛关注,尤其是在肿瘤发生和癌症治疗方面。本综述总结了 CAP 蛋白在各种癌症中的表达模式和作用。此外,它还分析了 CAP 蛋白影响癌细胞增殖和存活、调控上皮-间质转化、影响耐药性以及调控表观遗传学的机制。综述揭示了 CAP 蛋白在各种信号通路(如 MAPK、PI3K-Akt 和 p53 通路)中发挥的不同作用,而这些通路对肿瘤的进展至关重要。此外,这篇综述还总结了 CAP 蛋白的肿瘤抑制功能及其作为癌症生物标志物的潜力。这些研究结果表明,CAP 蛋白是创新性癌症诊断和治疗的一个前景广阔的新靶点。
期刊介绍:
Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.